title: Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
abstract: There are several new and emerging medication interventions for both the acute and maintenance treatment phases of schizophrenia. Recently approved are 2 new dopamine receptor partial agonists, brexpiprazole and cariprazine, as well as 2 new long-acting injectable antipsychotic formulations, aripiprazole lauroxil and 3-month paliperidone palmitate. Although differences in efficacy compared to other available choices are not expected, the new oral options offer different tolerability profiles that may be attractive for individual patients who have had difficulties with older medications. The new long-acting injectable options provide additional flexibility in terms of increasing the time interval between injections. In Phase III of clinical development is a novel antipsychotic, lumateperone (ITI-007), that appears to have little in the way of significant adverse effects. Deutetrabenazine and valbenazine are agents in Phase III for the treatment of tardive dyskinesia, a condition that can be found among persons receiving chronic antipsychotic therapy. On the horizon are additional injectable formulations of familiar antipsychotics, aripiprazole and risperidone, that may be more convenient than what is presently available.
authors.affiliation: Department of Psychiatry and Behavioral Sciences,New York Medical College,Valhalla,New York,USA.
authors.forename: Leslie
authors.initials: L
authors.lastname: Citrome
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D000068180:Aripiprazole / Q000008:administration & dosage / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D006801:Humans; D007273:Injections, Intramuscular; D000068882:Paliperidone Palmitate / Q000008:administration & dosage / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D013747:Tetrabenazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D010879:Piperazines; D015363:Quinolones; D013876:Thiophenes; C000591922:brexpiprazole; C000603978:valbenazine; D000068180:Aripiprazole; C000603935:aripiprazole lauroxil; C533287:cariprazine; D014633:Valine; C000609690:deutetrabenazine; D000068882:Paliperidone Palmitate; D013747:Tetrabenazine
keywords: Aripiprazole lauroxil; brexpiprazole; cariprazine; deutetrabenazine; long-acting injectable; lumateperone; paliperidone palmitate; risperidone; valbenazine